(NNE) Nano Nuclear Energy Common - Overview
Stock: Reactor, Microreactor, Battery, Fuel, Processing
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 99.3% |
| Relative Tail Risk | -12.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.30 |
| Alpha | -42.64 |
| Character TTM | |
|---|---|
| Beta | 1.829 |
| Beta Downside | 1.527 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.68% |
| CAGR/Max DD | 2.19 |
Description: NNE Nano Nuclear Energy Common January 16, 2026
Nano Nuclear Energy Inc. (NASDAQ: NNE) is a U.S.-based developer of advanced nuclear reactor concepts, including the KRONOS high-temperature gas-cooled micro-modular reactor (MMR), the compact LOKI MMR for remote applications, the solid-core battery-type ZEUS reactor, and the low-pressure salt-cooled ODIN system. In parallel, the firm is building a high-assay low-enriched uranium (HA-LEU) processing plant to create a domestic fuel supply chain, and it offers fuel logistics and nuclear consultancy services. The company was incorporated in 2022 and is headquartered in New York City, classifying it under the Heavy Electrical Equipment sub-industry.
Key sector drivers that could affect NNE’s upside include the U.S. Department of Energy’s recent $2 billion “Advanced Reactor Demonstration Program,” which earmarks funding for next-generation MMRs, and the broader decarbonization push that is expanding the projected global micro-reactor market to roughly $12 billion by 2035 (CAGR ≈ 13%). A critical KPI for NNE will be the timing and success of its HA-LEU licensing, as domestic fuel availability is a bottleneck for many U.S. reactor developers; as of Q4 2024, no commercial HA-LEU facility is operational, implying a high-risk, high-reward profile.
Given the early-stage nature of NNE’s technology pipeline and the regulatory uncertainties surrounding novel reactor designs, investors should monitor milestones such as DOE grant awards, NRC design-approval submissions, and any partnership announcements with utilities or defense customers. For a deeper, data-driven assessment of NNE’s valuation and risk metrics, a quick look at ValueRay’s analyst toolkit can be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -40.52 > 0.02 and ΔFCF/TA -4023 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.09 > 3% & CFO -19.6m > Net Income -40.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 53.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.7m) vs 12m ago 50.52% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.24%; Δ -0.24% > 0%) |
| Interest Coverage Ratio: -3.98 > 6 (EBITDA TTM -31.7m / Interest Expense TTM 8.05m) |
Altman Z'' -6.61
| A: 0.88 (Total Current Assets 204.7m - Total Current Liabilities 3.83m) / Total Assets 228.7m |
| B: -0.25 (Retained Earnings -57.5m / Total Assets 228.7m) |
| C: -0.24 (EBIT TTM -32.0m / Avg Total Assets 131.9m) |
| D: -9.44 (Book Value of Equity -57.5m / Total Liabilities 6.09m) |
| Altman-Z'' Score: -6.61 = D |
What is the price of NNE shares?
Over the past week, the price has changed by -0.66%, over one month by -8.52%, over three months by -24.02% and over the past year by -12.99%.
Is NNE a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NNE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46.7 | 59.8% |
| Analysts Target Price | 46.7 | 59.8% |
| ValueRay Target Price | 32.1 | 9.9% |
NNE Fundamental Data Overview February 04, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -32.0m USD
EBITDA TTM = -31.7m USD
Long Term Debt = 2.80m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 534.1m USD (from shortTermDebt, last fiscal year)
Debt = 2.80b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -200.47b USD (from netDebt column, last fiscal year)
Enterprise Value = 3.99b USD (1.40b + Debt 2.80b - CCE 203.3m)
Interest Coverage Ratio = -3.98 (Ebit TTM -32.0m / Interest Expense TTM 8.05m)
EV/FCF = -0.43x (Enterprise Value 3.99b / FCF TTM -9.27b)
FCF Yield = -232.0% (FCF TTM -9.27b / Enterprise Value 3.99b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 362.1k) / Revenue TTM)
Tobins Q-Ratio = 17.47 (Enterprise Value 3.99b / Total Assets 228.7m)
Interest Expense / Debt = 0.29% (Interest Expense 8.05m / Debt 2.80b)
Taxrate = 21.0% (US default 21%)
NOPAT = -25.3m (EBIT -32.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 53.48 (Total Current Assets 204.7m / Total Current Liabilities 3.83m)
Debt / Equity = 12.56 (Debt 2.80b / totalStockholderEquity, last quarter 222.6m)
Debt / EBITDA = 6333 (out of range, set to none) (Net Debt -200.47b / EBITDA -31.7m)
Debt / FCF = 21.64 (negative FCF - burning cash) (Net Debt -200.47b / FCF TTM -9.27b)
Total Stockholder Equity = 177.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.38% (Net Income -40.1m / Total Assets 228.7m)
RoE = -22.54% (Net Income TTM -40.1m / Total Stockholder Equity 177.7m)
RoCE = -17.73% (EBIT -32.0m / Capital Employed (Equity 177.7m + L.T.Debt 2.80m))
RoIC = -14.23% (negative operating profit) (NOPAT -25.3m / Invested Capital 177.7m)
WACC = 4.38% (E(1.40b)/V(4.20b) * Re(12.66%) + D(2.80b)/V(4.20b) * Rd(0.29%) * (1-Tc(0.21)))
Discount Rate = 12.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 34.17%
Fair Price DCF = unknown (Cash Flow -9.27b)
EPS Correlation: 14.69 | EPS CAGR: 23.88% | SUE: 0.99 | # QB: 1
Revenue Correlation: 13.10 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.32 | Chg30d=+0.013 | Revisions Net=+2 | Analysts=3
EPS current Year (2026-09-30): EPS=-1.45 | Chg30d=-0.158 | Revisions Net=+1 | Growth EPS=-37.1% | Growth Revenue=+0.0%
EPS next Year (2027-09-30): EPS=-1.46 | Chg30d=+0.165 | Revisions Net=+0 | Growth EPS=-0.1% | Growth Revenue=+0.0%